
Neurocrine Biosciences, Inc.
NASDAQ:NBIX
109.07 (USD) • At close March 12, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Neurocrine Biosciences, Inc. |
Symbool | NBIX |
Munteenheid | USD |
Prijs | 108.99 |
Beurswaarde | 10,866,684,465 |
Dividendpercentage | 0% |
52-weken bereik | 105.18 - 157.98 |
Industrie | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Dr. Kevin C. Gorman Ph.D. |
Website | https://www.neurocrine.com |
An error occurred while fetching data.
Over Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)